Pharmaceutical Social Network. Business information services for the medical and pharmaceutical industries and professionals.
22 members
19 members
18 members
15 members
14 members
13 members
13 members
12 members
12 members
11 members
Started by Pharmaceutical on Monday. 0 Replies 0 Likes
The latest set of opinions from the European Medicines Agency has been dominated by the news that a safety review of the benefits and risks of Novartis' oral multiple sclerosis treatment Gilenya has begun.The agency's Committee for Medicinal…Continue
Started by Nicolás Mena Jan 16. 0 Replies 0 Likes
The US Food and Drug Administration (FDA) has now sent its proposals for three prescription drug user fee programmes to Congress.They are the fifth authorisation of the Prescription Drug User Fee Act (PDUFA-V), plus two new programmes for human-use…Continue
Tags: fee, programmes, to, Congress, user
Started by Elisa Marferson Jan 13. 0 Replies 0 Likes
Novartis is to axe 1,960 jobs as part of a restructuring of its US operations, prompted by the pending patent loss on its hypertension blockbuster Diovan and predicted lower sales of the blood pressure drug Tekturna/Rasilez.The Swiss major said its…Continue
Started by Michael Honatan Jan 11. 0 Replies 0 Likes
Pfizer is highly unlikely to pursue any mega-mergers but will continue to look at bolt-on acquisitions and more research alliances, according to chief executive Ian Read.Speaking at the JP Morgan Global Healthcare Conference in San Francisco, Mr…Continue
Wednesday
Posted by Nicolás Mena on November 30, 2011 at 9:51pm 0 Comments 0 Likes
Lipitor, the world's best-selling drug, goes off-patent in the USA today, and observers are watching keenly to see how damaging the loss will be to Pfizer and how much generics firms will benefit.
Pfizer is fighting hard to keep hold of a…
ContinuePosted by Elisa Marferson on November 28, 2011 at 11:55pm 0 Comments 0 Likes
Novartis has been given the green light to market its triple combination antihypertensive Rasitrio.
The European Commission has approved Rasitrio as a single pill for the treatment of high blood pressure. It combines the Swiss…
ContinuePosted by Michael Honatan on November 24, 2011 at 8:56pm 0 Comments 0 Likes
Germany's Merck KGaA has asked a New York judge to force Facebook to provide information about "an apparent takeover" of its page on the social networking site, which is now occupied by information on rival Merck & Co.
Robert Horowitz…
ContinuePosted by Nicolás Mena on November 17, 2011 at 9:15pm 0 Comments 0 Likes
The European Commission has approved Pfizer's Vyndaqel for the treatment of a rare genetic disease.
Vyndaqel (tafamidis) has been given the green light for transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressive and fatal…
ContinuePosted by Nicolás Mena on November 14, 2011 at 8:29pm 0 Comments 0 Likes
The US Congressional Budget Office (CBO) now estimates that banning "pay-for-delay" deals between brand-name and generic drugmakers would reduce the federal deficit by $4.8 billion over 10 years; last year it said the measure would cut…
ContinuePosted by Nicolás Mena on November 8, 2011 at 8:18pm 0 Comments 0 Likes
AstraZeneca and partner Targacept have announced disappointing top-line results from the first of four late-stage studies on their new antidepressant.
Specifically, the Renaissance 3 Phase III study investigated TC-5214 as an adjunct…
Continue
© 2012 Created by ROSMA.
